Fedratinib Re-emerges as FDA-Approved Treatment of Myelofibrosis
Andrew Kuykendall, MD, discusses the background to the JAK2 inhibitor fedratinib (Inrebic), which was approved by the FDA in August 2019 for the treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including post–polycythemia vera or post–essential thrombocythemia MF.
Andrew Kuykendall, MD, assistant member at the Moffitt Cancer Center, discusses the background to the JAK2 inhibitor fedratinib (Inrebic), which wasapproved by the FDA in August 2019 for the treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis(MF), including postpolycythemia vera or post–essential thrombocythemia MF.
Kuykendall says fedratinib has an interesting story. It’s a relatively old drug that had previously been through extensive clinical trials years ago and has now re-emerged. He calls this a rising-from-the-ashes story to describe the evolution of fedratinib and its move toward the treatment landscape for patients with MF.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
